Genomics education for advance practice nurses: Staying cutting edge.

As we celebrate the 20th anniversary of sequencing of the human genome and the rapid integration of genetics in health care, we pause to reflect on the status of genomic competency in nursing. The literature provides evidence that nurses do not feel prepared or confident in genomics. Genomic education for nurses and other health care professionals can support access and equity in the integration of genomics into practice.

Essential genomic knowledge in graduate nursing practice.

Background: Genetics-informed nursing is essential to personalized health care. Advanced practice nurses will increasingly encounter genomic information in clinical care and are expected to have competency.

Purpose: To examine genomic competency of advanced practice nursing students and faculty in a graduate nursing school.

Patient perspectives on variant reclassification after cancer susceptibility testing.

Background: Little is known about the impact of reclassification on patients' perception of medical uncertainty or trust in genetics-based clinical care.

Methods: Semistructured telephone interviews were conducted with 20 patients who had received a reclassified genetic test result related to hereditary cancer. All participants had undergone genetic counseling and testing for cancer susceptibility at Vanderbilt-Ingram Cancer Center Hereditary Cancer Clinic within the last six years.

Genomics to personalize care of prostate cancer.

Prostate cancer is one of the most common cancers for men in the United States. Nurse practitioners need to understand oncology care and potential applications of genetic and genomics for men with prostate cancer. Genetic testing options are available to assist in decision making regarding screening for prostate cancer and the treatment of prostate cancer.

Use of PHQ-9 and pharmacogenetic testing in clinical practice.

Background: This project evaluated the clinical use of pharmacogenetic testing in an outpatient psychiatric practice, integrated a standardized measure for assessing depressive symptoms, and captured data regarding treatment efficacy.

Local Problem: According to the Centers for Disease Control and Prevention (2016), more than 10% of all outpatient office visits include a depression-related diagnosis. Patients who require more medication trials to experience remission of depressive symptoms are more likely to relapse in the follow-up period than those who do not (National Institute of Mental Health, 2001).

Metastatic Prostate Cancer: Effects of Genetic Testing on Care.

The National Comprehensive Cancer Network now recommends BRCA1/2 genetic testing in men with metastatic prostate cancer. The purpose of this article is to provide a review of principles of genetic testing in prostate cancer and highlight the significance of clinical genetic testing of BRCA1/2 and other genes (CHEK2, HOXB13, PALB2), including Lynch syndrome genes (MLH1, MSH2, MSH6, and PMS2) in men with metastatic prostate cancer. The potential impact of genetic testing on systemic treatments and the significance of the pathogenic results for at-risk family members is discussed.

Genomics of Prostate Cancer: What Nurses Need to Know.

Objective: To review the current state of genomics and genetic testing in prostate cancer.

Data Sources: National guidelines, evidence-based summaries, peer-reviewed studies, and Web sites. A case study is presented to illustrate key points.

Sleep-wake disturbances in cancer patients: narrative review of literature focusing on improving quality of life outcomes.

Purpose: Evidence suggests a high prevalence of sleep-wake disturbances in patients with cancer, occurring at diagnosis, during treatment, and continuing to survivorship. Yet associations between sleep-wake disturbances and the impact on quality of life outcomes is less clear. The purpose of this narrative review of the literature is to evaluate sleep-wake disturbances in patients with cancer, to describe the influence of poor sleep on quality of life as an outcome, and to evaluate the evidence to recommend future interventions.

Decision making after BRCA genetic testing. Down the road of transition.

The purpose of this study was to evaluate women who have completed hereditary cancer risk assessment and BRCA genetic testing to determine if they considered themselves prepared to proceed with decision making regarding cancer screening and prevention options. Levels of decisional conflict were explored, as was their preference for information delivery. The prospective, descriptive survey was conducted at a breast and clinical genetics clinic at a comprehensive cancer center in the northeastern United States.